[go: up one dir, main page]

ATE228353T1 - Verwendung von biologisch abbaubaren mikrosphären zur freisetzung eines krebsmittels zur behandlung des glioblastoms - Google Patents

Verwendung von biologisch abbaubaren mikrosphären zur freisetzung eines krebsmittels zur behandlung des glioblastoms

Info

Publication number
ATE228353T1
ATE228353T1 AT00401344T AT00401344T ATE228353T1 AT E228353 T1 ATE228353 T1 AT E228353T1 AT 00401344 T AT00401344 T AT 00401344T AT 00401344 T AT00401344 T AT 00401344T AT E228353 T1 ATE228353 T1 AT E228353T1
Authority
AT
Austria
Prior art keywords
glioblastoma
ancient
release
treatment
cancer agent
Prior art date
Application number
AT00401344T
Other languages
English (en)
Inventor
Nathalie Faisant
Jean-Pierre Benoit
Philippe Menei
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Application granted granted Critical
Publication of ATE228353T1 publication Critical patent/ATE228353T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00401344T 1999-05-17 2000-05-17 Verwendung von biologisch abbaubaren mikrosphären zur freisetzung eines krebsmittels zur behandlung des glioblastoms ATE228353T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9906207A FR2793684B1 (fr) 1999-05-17 1999-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant

Publications (1)

Publication Number Publication Date
ATE228353T1 true ATE228353T1 (de) 2002-12-15

Family

ID=9545636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00401344T ATE228353T1 (de) 1999-05-17 2000-05-17 Verwendung von biologisch abbaubaren mikrosphären zur freisetzung eines krebsmittels zur behandlung des glioblastoms

Country Status (30)

Country Link
US (2) US6803052B2 (de)
EP (2) EP1228755A1 (de)
JP (1) JP5230045B2 (de)
KR (1) KR100649948B1 (de)
CN (1) CN1210020C (de)
AR (1) AR024008A1 (de)
AT (1) ATE228353T1 (de)
AU (1) AU775320B2 (de)
BG (1) BG64936B1 (de)
BR (1) BR0010648A (de)
CA (1) CA2388656C (de)
CZ (1) CZ20014137A3 (de)
DE (1) DE60000842T2 (de)
DK (1) DK1053746T3 (de)
EA (1) EA004943B1 (de)
ES (1) ES2185544T3 (de)
FR (1) FR2793684B1 (de)
HK (1) HK1047044B (de)
HU (1) HUP0201224A3 (de)
IL (2) IL146467A0 (de)
MX (1) MXPA01011919A (de)
NO (1) NO331686B1 (de)
NZ (1) NZ515515A (de)
PL (1) PL201614B1 (de)
PT (1) PT1053746E (de)
SI (1) SI1053746T1 (de)
SK (1) SK16342001A3 (de)
TW (1) TWI229608B (de)
WO (1) WO2000069413A1 (de)
ZA (1) ZA200109415B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345449B1 (de) 1999-08-05 2019-05-01 ResMed R&D Germany GmbH Atemgasschlauch, Anschlussvorrichtung hierfür und Anschlussstrukturbauteil
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
KR20040007596A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
ES2427930T3 (es) * 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
EP1411861B1 (de) 2001-06-29 2012-04-04 Medgraft Microtech, Inc. Biologisch abbaubare injizierbare implantate und verwandte herstellungs- und verwendungsmethoden
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
US8986737B2 (en) 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
CA3081288C (en) 2003-06-20 2022-10-18 ResMed Pty Ltd Breathable gas apparatus with humidifier
US20070026005A1 (en) * 2003-09-09 2007-02-01 Sung Young C Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
CN1909920A (zh) * 2004-03-18 2007-02-07 圣卢加医院 缓释剂的传送方法
US7833187B2 (en) * 2004-04-16 2010-11-16 Nuvue Therapeutics, Inc. Systems and methods for improving image-guided tissue ablation
US8088413B2 (en) * 2004-04-16 2012-01-03 Nuvue Therapeutics, Inc. Methods for improved cryo-chemotherapy tissue ablation
EP1796644B1 (de) 2004-09-07 2011-04-13 Biocompatibles UK Limited Arzneimittelabgabe aus embolischen mitteln
US8702580B2 (en) * 2004-10-06 2014-04-22 Brainlab Ag Method and device for assisting in a tissue treatment
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
CN1299685C (zh) * 2005-01-26 2007-02-14 上海大学 氟尿嘧啶载药微球及其制备方法
CN100340297C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 抗癌体内植入剂
CN1923282B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含激素类药物的抗癌缓释注射剂
CN1923281B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含植物生物碱的抗癌缓释注射剂
CN100464785C (zh) * 2005-08-30 2009-03-04 孔庆忠 一种抗癌药物缓释注射剂及其应用
CN1923173B (zh) * 2006-02-24 2010-05-19 济南康泉医药科技有限公司 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
US20090036380A1 (en) * 2006-03-14 2009-02-05 Yeda Research And Development Co., Ltd. Composition And Method For Brain Tumor Therapy
CN100464736C (zh) * 2006-03-17 2009-03-04 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂
EP1985286A1 (de) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Mikrokügelchen zur Behandlung von Gehirntumoren
DK2790668T3 (da) 2011-12-13 2020-11-23 Engeneic Molecular Delivery Pty Ltd Bakterielt afledte, intakte miniceller til levering af terapeutiske midler til hjernetumorer
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
WO2017083717A1 (en) * 2015-11-11 2017-05-18 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
CN118903386A (zh) 2017-08-24 2024-11-08 诺和诺德股份有限公司 Glp-1组合物及其用途
KR20220143811A (ko) 2019-12-05 2022-10-25 웨스트 버지니아 유니버시티 단백질 로딩된 plga 나노구체
BR112022013746A2 (pt) 2020-02-18 2022-10-11 Novo Nordisk As Formulação aquosa de cagrilintida, formulação aquosa de semaglutida, dispositivo médico, e, combinação de dose fixa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
EP0938333B1 (de) * 1996-10-16 2004-02-04 Regeneron Pharmaceuticals, Inc. Verfahren zur verabreichung von wachstumsfaktoren
TW519543B (en) * 1997-03-31 2003-02-01 Toray Industries Quinolinomorphinan derivative and pharmaceutical composition for curing-preventing cerebral disorder
KR20010031103A (ko) * 1997-10-14 2001-04-16 버틀러 그레고리 비. 네우레굴린을 사용하는 치료요법적 방법

Also Published As

Publication number Publication date
HUP0201224A2 (hu) 2002-11-28
BR0010648A (pt) 2002-02-19
DE60000842T2 (de) 2003-08-28
SI1053746T1 (en) 2003-04-30
NZ515515A (en) 2004-02-27
PT1053746E (pt) 2003-04-30
NO331686B1 (no) 2012-02-20
CA2388656C (fr) 2011-04-26
CA2388656A1 (fr) 2000-11-23
TWI229608B (en) 2005-03-21
CZ20014137A3 (cs) 2002-06-12
BG106106A (en) 2002-05-31
PL352372A1 (en) 2003-08-25
US7041241B2 (en) 2006-05-09
HUP0201224A3 (en) 2004-05-28
AR024008A1 (es) 2002-09-04
FR2793684B1 (fr) 2001-08-10
US6803052B2 (en) 2004-10-12
AU775320B2 (en) 2004-07-29
MXPA01011919A (es) 2002-05-06
FR2793684A1 (fr) 2000-11-24
KR20020000178A (ko) 2002-01-04
JP2002544219A (ja) 2002-12-24
AU4764100A (en) 2000-12-05
EA200101206A1 (ru) 2002-04-25
DE60000842D1 (de) 2003-01-09
ZA200109415B (en) 2003-01-29
CN1210020C (zh) 2005-07-13
BG64936B1 (bg) 2006-10-31
EA004943B1 (ru) 2004-10-28
US20030175356A1 (en) 2003-09-18
DK1053746T3 (da) 2003-03-31
NO20015501D0 (no) 2001-11-09
IL146467A0 (en) 2002-07-25
SK16342001A3 (sk) 2002-08-06
HK1047044A1 (en) 2003-02-07
EP1053746B1 (de) 2002-11-27
WO2000069413A1 (fr) 2000-11-23
KR100649948B1 (ko) 2006-11-24
IL146467A (en) 2006-06-11
EP1228755A1 (de) 2002-08-07
US20020051749A1 (en) 2002-05-02
NO20015501L (no) 2002-01-09
EP1053746A1 (de) 2000-11-22
HK1047044B (zh) 2005-12-23
CN1356892A (zh) 2002-07-03
PL201614B1 (pl) 2009-04-30
ES2185544T3 (es) 2003-05-01
JP5230045B2 (ja) 2013-07-10

Similar Documents

Publication Publication Date Title
ATE228353T1 (de) Verwendung von biologisch abbaubaren mikrosphären zur freisetzung eines krebsmittels zur behandlung des glioblastoms
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
GB2421260B (en) Well treating compositions for slow release of treatment agents and methods of using the same
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60036968D1 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
ATE455106T1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE338552T1 (de) Verwendungen von et743 zur behandlung von krebs
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
DE60021908D1 (de) Hydroxyeicosatetraenoatsalze, zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
GB2448442B (en) Well treating compositions for slow release of treatment agents and methods of using the same
ATE226440T1 (de) Zusammensetzung zur behandlung von psoriasis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1053746

Country of ref document: EP